MedTrace Logo

TENS Use for Post-cesarean Pain Management

NCT07777939 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2026-08-24

No results posted yet for this study

Summary

The aim of this randomized controlled trial is to evaluate the effectiveness of continuous 24-hour Transcutaneous Electrical Nerve Stimulation (TENS) as an adjunct to standard postoperative care for pain management following cesarean delivery. Eligible women undergoing cesarean delivery under spinal anesthesia will be randomly assigned in a 1:1 ratio to either the intervention group, which will receive continuous TENS in addition to standard postoperative analgesia, or the control group, which will receive standard postoperative analgesia alone. The primary outcome is the Quality of Recovery-15 (QoR-15) score assessed 24 hours after cesarean delivery.

Conditions

  • Post Cesarean Pain Management

Interventions

DEVICE

TENS

Participants randomized to the intervention group will receive continuous transcutaneous electrical nerve stimulation (TENS) in addition to standard postoperative analgesia. TENS will be initiated within 2 hours after cesarean delivery and applied continuously for the first 24 postoperative hours. Participants will be instructed to wear the device continuously and may temporarily remove the device for showering. All participants will receive in addition the institution's standard postoperative care and analgesic regimen following cesarean delivery.

Sponsors & Collaborators

  • Holy Family Hospital, Nazareth, Israel

    lead OTHER

Principal Investigators

  • Raed Salim · The Azrieli Faculty of Medicine, Bar Ilan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-08-31
Completion
2027-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07777939 on ClinicalTrials.gov